Therefore, it is possible that IKZF1 could work as a negative transcriptional regulator of the RAS pathway by binding to the PTPN11 promoter and directly suppressing its activity, and thus tumor cells may not need both altered pathways to drive disease relapse [39]. This evidence concerns the gene IKZF1 and neoplasm.